Trial Profile
A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Monalizumab (Primary) ; Oleclumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NeoCOAST 2
- Sponsors AstraZeneca
- 14 Feb 2024 Planned number of patients changed from 350 to 490.
- 30 Oct 2023 Planned End Date changed from 30 Mar 2026 to 22 Dec 2028.
- 30 Oct 2023 Planned primary completion date changed from 30 Mar 2026 to 22 Dec 2028.